VILE SE						
JAN 2 6 2004 R	se type a plus ler <u>the Paper</u>	sign (+) inside this bo	× →	O persons are required to re	App Patent and Tradem spond to a collection of informatic	PTO/SB/08A (10-96) a proved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
PACEDIA	Substitu	ute for form 1449A/PT		_	C	omplete if Known
			-		· Application Number	10/747,994
				SCLOSURE	Filing Date	12-30-2003
	STA	ATEMENT B	Y X	APPLICANT	First Named Inventor	PARKAR, et al.
					Group Art Unit	Not Yet Known
		(use as many she	ets a.	s necessary)	Examiner Name	Not Yet Known
+	Sheet	1	of	3	Attorney Docket Number	USAV2003/0073 - US - NP

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Paten Number	t Document  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
BL		5,958,723		Merck Frosst Canada & Co.	09-28-1999				
BL		6,214,972		Merck Frosst Canada & Co.	04-10-2001				
BC		6,395,499		Merck Frosst Canada & Co.	05-28-2002				
						·····			
						· · · · · · · · · · · · · · · · · · ·			
		•	-+						
$\longrightarrow$			-+						
-					+				
						· · · · · · · · · · · · · · · · · · ·			

FOREIGN PATENT DOCUMENTS								
Examiner	xaminer Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т
nitials"	No.1	Office	Number <sup>4</sup>	Kind Code <sup>s</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T
BC		wo	96/23066		Merck Frosst Canada Inc.	08-01-1996		${ m I}$
								L
		$\vdash$		<del></del>				+
						<del> </del>		╁
			4.					$\dagger$
						<u> </u>		T
								Ι
						I		1

Examiner		Date	
Signature	South	Considered	6.16.06

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/	0, , ,	
,	TAH S & SOLY	ash type a plus sign (+) inside this box ->
g B		er the Paperwork Reduction Act of 1995, no persons
V.	TRACE OF IS	Substitute for form 1449B/PTO
	VIA.	INFORMATION DISCL

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

**Application Number** 10/747,994 12-30-2003 Filing Date PARKAR, et al. First Named Inventor Not Yet Known Group Art Unit **Examiner Name** Not Yet Known

Complete if Known

(use as many sheets as necessary)

Sheet of 2 3 Attorney Docket Number USAV2003/0073 - US - NP

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS							
Examiner Cite No.1							
		ARIMURA Akinon et al., Prevention Of Allergic Inflammation By A Novel Protaglandin Receptor Antagonist, S-5751, The Journal Of Pharmacology And Experimental Therapeutics, (2001), Vol. 298, No. 2, pp. 411 - 419					
(.		ARMSTRONG Roma A., Platelet Prostanoid Receptors, Pharmacol. Ther., (1996), Vol. 72, No. 3, pp. 171 - 191					
		BRIGHTLING C. E. et al., New Insights Into The Role Of The Mast Cell In Asthma, Clin. Exp. Allergy, (2003), Vol. 33, pp. 550 - 556					
		COLEMAN Robert A. et al., International Union Of Pharmacology Classification Of Prostanoid Receptor: Properties, Distribution, And Structure Of The Receptors And Their Subtypes, Pharmacological Reviews, (1994), Vol. 46, No. 2, pp. 205 - 229					
		DOYLE William J. et al., Physiologic Responses To Intranasal Dose-Response Challenges With Histamine, Methacholine, Bradykinin, And Prostaglandin In Adult Volunteers With And Without Nasal Allergy, Journal Of Allergy And Clinical Immunology, (1990), Vol. 86, pp. 924 - 935					
		HIRATA Masakazu et al., Molecular Characterization Of A Mouse Prostaglanding D Receptor And Functional Expression Of The Cloned Gene, Proc. Nat'l. Acad. Sci. USA, (1994), Vol. 91, pp. 11192 - 11196					
		HOLGATE Stephen T. et al., Bronchial Epithelium As A Key Regulator Of Airway Allergen Sensitization And Remodeling Is Asthma, Am. J. Respir. Crit. Care Med., (2000), Vol. 162, pp. S113 - S117					
		KOBAYASHI Takuya et al., Amino Acid Residues Conferring Ligand Binding Properties Of Prostaglandin I And Prostaglandin D Receptors, The Journal Of Biological Chemistry, (2000), Vol. 276, No. 32, pp. 24294 - 24303					
		LEWIS Robert A. et al., Prostaglandin D2 Generation After Activation Of Rat And Human Mast Cells With Anti-IgE, The Journal Of Immunology, (1982), Vol. 129, No. 4, pp. 1627 - 1631					
$\bigvee$		MATSUOKA Toshiyuki et al., Prostaglandin D2 As A Mediator Of Allergic Asthma, Science, (2000), Vol. 287, pp. 2013 - 2019					

Examiner Signature	Double	Date Considered	6.16.06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial II reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

\0\	
(	2 6 2004 PH
HAL SH	Please tage a plus sign (+) inside this box →
B	Under the Paperwork Reduction Act of 1995, no persons are rec

Sheet

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB control number.

USAV2003/0073 - US - NP

Complete if Known CHACES Substitute for form 1449B/PTO **Application Number** 10/747,994 **INFORMATION DISCLOSURE** 12-30-2003 **Filing Date** STATEMENT BY APPLICANT **First Named Inventor** PARKAR, et al. Group Art Unit Not Yet Known **Examiner Name** Not Yet Known (use as many sheets as necessary) Attorney Docket Number of

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2				
Be		NARUMIYA Shuh et al., Structure And Function Of Prostanoid Receptors, Journal Of Lipid Mediators, (1993), Vol. 6, pp. 155 - 161					
		NEGISHI Manabu et al., Prostanoid Receptors And Their Biological Actions, Prog. Lipid Res., (1993), Vol. 32, No. 4, pp. 417 - 434					
		ROBERTS L. Jackson et al., Increased Production Of Prostaglandin D2 In Patients With Systemic Mastocytosis, The New England Journal Of Medicine, (1980), Vol. 303, No. 24, pp. 1400 - 1404					
		WRIGHT D. Hamish et al., A Novel Biological Role For Prostaglandin D2 Is Suggested By Distribution Studies Of The Rat DP Prostanoid Receptor, European Journal Of Pharmacology, (1999), Vol. 377, pp. 101 - 115					

Examiner		Date	0 11 01
Signature	Loude	Considered	6-16-06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.